MedTrace Logo

Nerve Growth Factor for the Treatment of Cornea Disease

NCT04552730 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2021-12-14

No results posted yet for this study

Summary

To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.

Conditions

Interventions

DRUG

Cenegermin-Bkbj

Topical Cenegermin-bkbj 6 times per day for 8 weeks.

Sponsors & Collaborators

Principal Investigators

  • Christopher N Ta, MD · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-14
Primary Completion
2021-05-04
Completion
2021-05-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04552730 on ClinicalTrials.gov